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What’s already known on this topic? 
Low levels of PAPP-A are associated with small for gestational age and pre-eclampsia. 
 
What does this study add? 
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NT, CRL and PAPP-A are independent prognostic markers for adverse pregnancy outcome. 
Further work is required to assess the predictive ability of these factors in prediction 
models. 
 
Abstract 
Objective 
Are first trimester serum pregnancy-associated plasma protein-A (PAPP-A), nuchal 
translucency (NT) and crown rump length (CRL) prognostic factors for adverse pregnancy 
outcomes? 
Method 
Retrospective cohort women, singleton pregnancies (UK 2011-2015). Unadjusted and 
multivariable logistic regression, outcomes: small for gestational age (SGA), pre-eclampsia 
(PE), pre-term birth (PTB), miscarriage, stillbirth, perinatal mortality and neonatal death 
(NND). 
Results 
12,592 pregnancies: 852 (6.8%) PTB, 352 (2.8%) PE, 1824 (14.5%) SGA, 73 (0.6%) 
miscarriages, 37(0.3%) stillbirths, 73 perinatal deaths (0.6%) and 38 (0.30%) NND. 
Multivariable analysis: lower odds of SGA [adjusted odds ratio (aOR) 0.88 (95% CI 
0.85,0.91)], PTB [0.92 (95%CI 0.88,0.97)], PE [0.91 (95% CI 0.85,0.97)] and stillbirth [ 0.71 
(95% CI 0.52,0.98)] as PAPP-A increases. Lower odds of SGA [aOR 0.79 (95% CI 0.70,0.89)] 
but higher odds of miscarriage [aOR 1.75 95% CI (1.12,2.72)] as NT increases, and lower 
odds of stillbirth as CRL increases [aOR 0.94 95% CI (0.89,0.99)]. Multivariable analysis of 
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three factors together demonstrated strong associations: a) PAPP-A, NT, CRL and SGA, b) 
PAPP-A and PTB, c) PAPP-A, CRL and PE, d) NT and miscarriage. 
Conclusions  
PAPP-A, NT and CRL independent prognostic factor for adverse pregnancy outcomes, 
especially PAPP-A and SGA with lower PAPP-A associated with increased risk.  
 
 
Keywords: PAPP-A, small for gestational age, stillbirth, pre-eclampsia, pre-term delivery. 
Introduction 
Adverse pregnancy outcomes have a psychological impact for the family as well as an 
increased cost of healthcare. Methods of prediction would allow obstetricians to provide 
increased obstetric surveillance, focusing optimum management and possibly improving the 
outcome of the pregnancy. 
Pregnancy associated plasma protein A (PAPP-A) is a placental glycoprotein 
produced by syncytial trophoblast of the placenta, which cleaves insulin-like growth factor 
binding protein 4 (IGFBP4) and is a positive regulator of insulin-like growth factors (IGFs) 1, 
potentially influencing fetal growth and wellbeing. 
Studies have tested the hypothesis that low maternal serum levels of PAPP-A in the 
first trimester are prognostic factors for adverse pregnancy outcomes associated with poor 
placental function 2 3, 4 5 6. International Guidelines on “The Investigation and Management 
of the Small for Gestational Fetus” have recommended that pregnant women with a serum 
PAPP-A <0.4MoM (5th centile) in the first trimester receive increased ultrasound 
surveillance for fetal growth disorders7.  This recommendation was based on a previous 
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systematic review by our group in 2008 assessing Down’s syndrome markers to predict pre-
eclampsia and SGA8. This review included only 16 studies, did not assess all outcomes and 
did not distinguish between prognosis and prediction. However, contradictory results have 
been observed in publications 6, 9 and few studies have investigated the association of first 
trimester fetal biometry [nuchal translucency (NT) and crown rump length (CRL)] with 
adverse outcomes and their relationship with PAPP-A 3, 10. Resolution of this is required, 
because genuine prognostic factors in this field have many potential uses. As outlined by the 
PROGRESS series 11-14, they may guide clinical decisions and monitoring strategies, inform 
the design and analysis of new trials, and improve models for individualised risk prediction. 
Factors that add additional (independent) prognostic information are difficult to find, but 
are needed to improve the discrimination performance of a ‘prognostic model’13 that 
produces absolute risk predictions for women based on a set of individual characteristics11. 
Our objective was to undertake a large cohort study to determine whether serum PAPP-A, 
NT and CRL in the first trimester are independent prognostic factors for the risk of 
subsequent adverse pregnancy outcomes. 
 
Methods 
Data collection 
In a retrospective cohort study, data were collected from patients booked from 1st 
August 2011 (commencement of electronic maternity record) to 31st March 2015 at the 
Birmingham Women’s Foundation Trust (BWNFT), a secondary and tertiary care NHS 
hospital in West Midlands, UK. 
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All pregnant women who accepted first trimester aneuploidy screening and 
delivered in BWNFT were included in the study. First trimester aneuploidy screening is 
offered to all pregnant women between 11+2 to 14+1 weeks of gestation (crown–rump 
length (CRL) measures from 45 mm to 84 mm) as part of the National Downs Syndrome 
Screening Programme15, 16. This involves measuring maternal serum levels of PAPP-A and 
free beta human chorionic gonadotrophin (fβHCG), along with the NT, and the pregnancy is 
dated on the basis of CRL. All first trimester scans and measurements performed at BWNFT 
are performed by accredited sonographers according to National NEQAS guidelines17. First 
day of the last menstrual period was obtained from the referring letter from the community 
midwife or hospital. This date was confirmed with the mother at the ultrasound visit and 
additional information on the regularity and cycle duration was obtained.  
Analysis for PAPP-A was performed on the Auto-Delfia immunoassay platform 
(Perkin Elmer Ltd, Seer Green, UK). For the purpose of Down’s syndrome screening, PAPP-A 
values are converted to multiples of the median for gestation. In this study, to prevent any 
loss of data18 and to remove the need for considering an absolute threshold, PAPP-A values 
were considered as a continuous variable using the absolute value (mU/L). To aid the 
presentation and interpretation of results, PAPP-A values were rescaled by dividing the 
values by 1000, therefore the results relate to PAPP-A values in U/L. 
Multiple hospital-based, secure and confidential computerized databases were used 
to extract the information for the study and governance from the hospital-based IT and 
Caldecott Guardian were prospectively obtained. Maternal and pregnancy outcome data 
were collected from K2 database, Neonatal data were collected from Badgernet database, 
and biochemistry data were collected from a biochemistry database. The collected data 
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consisted of maternal characteristics and demographics; maternal medical, antepartum, 
peripartum and pregnancy outcome data along with first trimester serum PAPP-A levels, NT 
and CRL. Multiple gestations, pregnancies with donor eggs, missing outcome and known 
fetal aneuploidy were excluded. Cases of aneuploidy were cross referenced with the West 
Midlands Regional Genetics Laboratory database. 
Definitions of maternal and obstetric characteristics 
Preterm birth (PTB) was defined as live delivery prior to 37 weeks, both spontaneous 
and iatrogenic. Pre-eclampsia (PE) was defined according to the International Society for the 
study of Hypertension in Pregnancy (ISSHP) definition as de-novo hypertension at or after 20 
weeks gestation (at least 2 readings of Blood Pressure >140 mmHg systolic or >90 mmHg 
diastolic) with proteinuria (spot urine protein/creatinine >30 mg/mmol [0.3 mg/mg] or >300 
mg/day or at least 1 g/L [‘2 + ’] on dipstick testing)19. Small for gestational age (SGA) was 
defined as birthweight below the 10th percentile of the customised growth chart20. 
Miscarriage was defined as fetal demise before 24 weeks of gestation. Stillbirth was defined 
as intrauterine death after 24 completed weeks of pregnancy. Perinatal death was defined 
as fetal or neonatal death between 24 weeks of gestation and 7 days after birth. Neonatal 
death was defined as death between birth and 28 days. 
Data Analysis 
Mother and fetus demographics and clinical features 
Distributions of demographic characteristics and known prognostic factors were 
summarised. The existing prognostic factors were those deemed to be important by the 
clinical team a prior and defined as: maternal age at test, gestational age at test, parity, 
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body mass index (BMI), deprivation category (Index of Multiple Deprivation 2010 – IMD 16, 
calculated using National Perinatal Epidemiology Unit calculator), ethnicity, assisted 
conception (IVF), smoking status (non-smoker, stopped at booking or on-going smoker), pre-
pregnancy insulin-dependent diabetes mellitus, and gender of the baby. Mean and standard 
deviation (SD), or median and interquartile range (IQR), is reported for continuous variables, 
according to whether the variables were normally distributed. The number and percentage 
are reported for categorical variables. 
Analysis of prognostic association with outcomes 
Univariable logistic regression analysis was used to estimate the unadjusted odds 
ratio (OR) for each potential prognostic factor (PAPP-A/NT/CRL) separately. The odds ratios 
indicate how much the odds of the outcome are increased for each 1-unit increase in the 
factor.  
Again for each of the three factors separately, multivariable logistic regression 
analyses were fitted to examine the odds ratio adjusted for the known (or likely) existing 
prognostic factors of maternal age (years), parity, BMI, smoking status, IVF, ethnicity, 
deprivation category and gestational diabetes. This provided the adjusted odds ratio for a 1-
unit increase in each factor, to reveal their independent prognostic value over and above 
other factors. 
Then, for each outcome, the three factors were analysed in combination in one 
multivariable logistic regression model, whilst adjusting for the other factors detailed above, 
to explore whether the prognostic value of each factor is the same after adjusting for the 
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other two potential prognostic factors. The linearity assumption of all continuous variables 
was assumed for these multivariable models. 
Therefore, finally, the fully adjusted models with all three potential factors in 
combination were fitted again; however, additionally, the linearity assumption of the 
prognostic effects for the three factors of interest was assessed, and alternative functional 
forms were considered if the assumption was violated. Else, a linear relationship was 
specified for all three prognostic factors of interest. The functional form was chosen using 
fractional polynomials, where all possible fractional polynomials up to the second degree 
were considered based on their statistical significance21. A linear relationship was specified 
for the other continuous covariates (maternal age and BMI). 
In all multivariable models described above, no model selection process was used to 
determine which factors were included in each model, since all variables were pre-specified. 
Handling of missing data 
The percentages of missing values for each covariate and outcome were calculated. 
Missing data was imputed with multiple imputation with chained equations with 35 
imputed datasets equal to the percentage of patients with missing data 22. For non-normally 
distributed variables, predictive mean matching was used to impute the missing data 23. The 
imputation model contained all complete outcomes and covariates that were included in 
the multivariable analyses. Rubin’s rules were used to combine the parameter estimates 
and standard errors into a single inference 24. A complete-case analysis was also conducted 
as a sensitivity analysis. 
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Estimates of prognostic effects are reported as odds ratios (OR) with 95% confidence 
intervals (CI) and p-values. Analyses were performed using Stata version 14 25 and all 
regression models were fitted using maximum likelihood estimation. 
 
Results 
Between August 2011 and March 2015, first-trimester combined screening was 
performed in 12,837 pregnant women. Ten pregnancies conceived with donor eggs were 
excluded. Three pregnancies with an unclear pregnancy outcome showing neonatal death 
post 28 days were excluded since this outcome would not be routinely recorded in the 
databases. After excluding 232 multiple pregnancies, the final study cohort was of 12,592 
singleton pregnancies. 
As depicted in Table 1, the mean maternal age and median BMI were 30.6 (SD 5.6) 
and 25.1 (IQR 22.4 to 28.8), respectively. The majority of the women were White British 
European (62.6%) followed by South Asian (19.9%). Mean gestational age at first trimester 
ultrasound was 88.2 days (SD 4.3). About 2% (n=250) of pregnancies were the result of 
assisted conception. Smoking status was known for all women and 12.4% were on-going 
smokers in the pregnancy, 84.3% non-smokers and 3.3% had given up at the time of first 
trimester booking appointment. Nearly half (43%, n=5495) patients lived in the most 
deprived areas (deprivation score ≥ 34.18) and 3.6% (n=455) patients lived in the least 
deprived areas (deprivation score ≤ 8.49). Gender distribution was almost equal in the 
fetuses (48.6% male and 51.1% female). 
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BMI was missing in 4466 (35.5%) records, parity was missing in 567 (4.5%) and 
deprivation score was missing in 175 (1.4%) records. There were missing data for 152 (1.2%) 
fetal weight and four (0.03 %) neonatal outcomes. Multiple imputation was performed for 
missing BMI (height, weight), parity and deprivation score values. Although some variables 
were normally distributed, predictive mean matching was used for all variables because 
imputation with chained regression analysis imputed unrealistic values for weight and 
height. 
Table 2 displays the number of events for each outcome for the cohort, and the 
prognostic association of PAPP-A, NT and CRL with these outcomes in the unadjusted 
analyses. Of 12,592 women, 852 had pre term birth (6.8%), 352 patients had pre-eclampsia 
(2.8%) and 1824 babies were SGA (14.5%). There were 73 pregnancies that ended in 
miscarriage (0.6%) and 37 stillbirths (0.3%). There were 38 neonatal deaths (0.31%) of which 
36 were early and thus giving a total of 73 perinatal deaths (0.6%). 
 
PAPP-A Results 
In the unadjusted analysis (Table 2), a one unit increase in the concentration of 
PAPP-A (U/L) was estimated to lower the odds of an SGA neonate by 13%, which was highly 
significant [OR 0.87 (95% CI 0.85, 0.90), p<0.0001]. Similar conclusions can be drawn for the 
association between PAPP-A and pre-term birth [OR 0.93 (95%CI 0.90, 0.97), p<0.0001] In 
addition, PAPP-A and pre-eclampsia demonstrated a similar relationship [OR 0.92 (95% CI 
0.86, 0.97), p=0.004]. The results for stillbirth were in the same direction and quantitatively 
similar, although the CI was slightly wider and the p-value was just above the 5% [OR 0.81 
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(95% CI 0.66, 1.0), p=0.052]. There was no evidence of a strong association between PAPP-A 
and miscarriage, perinatal death or neonatal death. 
After adjusting for mother’s age, BMI, parity, ethnicity, deprivation score, smoking 
status, IVF status, and gestational diabetes in the multivariable analysis there was evidence 
of strong independent prognostic associations between: PAPP-A and SGA [OR 0.88 (95%CI 
0.85, 0.91), p<0.0001] (Table 3; full model parameter estimates for all adjusted models are 
shown in the Supporting Information Tables S1-S7 ); PAPP-A and PTB [OR 0.92 (95% CI 0.88, 
0.97), p=<0.0001]; and PAPP-A and PE [OR 0.91 (95% CI 0.85, 0.97), p=0.003]. There was also 
evidence of a lower odds of a stillbirth as PAPP-A increases [OR 0.71 (95% CI 0.52, 0.98), 
p=0.038]. The association of PAPP-A with the outcomes of miscarriage (Table S4), perinatal 
death (Table S6) and neonatal death (Table S7) remained non-significant in the multivariable 
analyses. 
NT Results 
In the unadjusted analyses (Table 2), for higher values of NT there was a strong 
association with an increased odds of miscarriage [OR 1.94 (95% CI 1.54, 2.45), p<0.0001], 
and a significant decreased odds of SGA [OR 0.81 (95% CI 0.72, 0.91), p<0.0001]. There was 
also some evidence that higher values are associated with an increased risk of PTB [OR 1.15 
(95% CI 1.00, 1.32), p=0.053] though the CI overlapped one.  
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After multivariable analysis, there was independent prognostic value of NT for SGA 
[OR 0.79 (95% CI 0.70, 0.89), p<0.0001] (Table 3 and Table S8), and for miscarriage [OR 1.75 
(95% CI 1.12, 2.72), p=0.013] (Table S11). There was no significant relationship between NT 
and PTB, PE, stillbirth, perinatal or neonatal death in the unadjusted or adjusted analyses 
(Table S9, S10, S12, S13, S14). 
CRL Results 
For CRL in the unadjusted analysis there was no significant association with any of 
the outcomes (Table 2). There was a borderline statistical significance for SGA which 
remained after adjustment [OR 0.99 (95% CI 0.99, 1.00, p=0.057)] (Table 3), but the 
magnitude of the OR was close to one. After adjustment for other known predictors and 
potential confounders, there was evidence of a strong association between CRL and 
stillbirth [OR 0.94 (95% CI 0.89, 0.99), p=0.027], thus between 1% and 11% lower odds of 
stillbirth for a one unit increase in CRL. The adjusted analyses for PTB, PE, miscarriage, 
perinatal death and neonatal death demonstrated no significant association with CRL (Table 
S15 - S21). 
PAPP-A, NT and CRL in combination 
Assuming linear functions for all continuous variables, the three potential prognostic 
factors were then considered in combination with adjustment for confounders and known 
prognostic factors as discussed (Tables S22-28 in the Supporting Information). For SGA, this 
analysis demonstrated strong associations with PAPP-A [OR 0.87 (95% CI 0.84, 0.90), 
p<0.0001); NT [OR 0.80 (95% CI 0.70, 0.91); p=0.001] and CRL [OR 1.01 (95% CI 1.00, 1.03); 
p=0.004). 
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For preterm birth (Table S23), only PAPP-A was significantly associated with reduced 
odds [OR 0.92 (95% CI 0.87, 0.96), p<0.0001], as seen when the factors were considered 
individually. For pre-eclampsia, PAPP-A was still significantly associated [OR 0.88 (95% CI 
0.82, 0.94); p=<0.0001] and now there was evidence of increased odds of pre-eclampsia as 
CRL increases [OR 1.02 (95% CI 1.01, 1.04); p=0.004] (Table S24). 
There remained a statistically significantly increased odds of miscarriage as NT 
increases [OR 1.67 (95% CI 1.01, 2.76), p=0.047], and no evidence of associations between 
miscarriage and PAPP-A or CRL (Table S25). There was not any strong evidence (e.g. based 
on statistical significance at the 5% level) of any associations between stillbirth and any of 
PAPP-A, NT or CRL, unlike the individual models (Table S26). There was no evidence of 
associations between any of the three factors of interest and perinatal or neonatal death 
(Table S27-28). 
After checking the linearity assumption of the three prognostic factors, all the 
previously identified prognostic associations remained the same. However, the log 
transformation was statistically the best fitting functional form of PAPP-A for SGA, and 
1/  was statistically the best fitting functional form of PAPP-A for PTB. For PAPP-A for 
all other outcomes and for CRL and NT for all outcomes, the best fitting functional form was 
the linear function (See Tables S29-S31). 
All the findings remained the same in the complete case analysis. 
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Discussion 
Main Findings 
This large cohort study provides strong evidence that lower values of PAPP-A are 
associated with an increased odds of SGA, stillbirth, PE and PTB. As NT increases there is 
evidence of a lower odds of SGA but higher odds of miscarriage. As CRL decreases there is 
evidence of higher odds of stillbirth. Neonatal and perinatal deaths were not associated 
with any of the prognostic factors measured in the first trimester. When considered in 
combination there is a statistically significant association of PAPP-A, NT and CRL with SGA; 
preterm birth with PAPP-A, pre-eclampsia with PAPP-A and CRL, and miscarriage with NT. In 
the combined model stillbirth is no longer associated with any of the factors. 
 
Strengths and Limitations:  
Our study has several strengths. This is a large cohort study looking at multiple 
pregnancy outcomes providing reproducible statistical results. The UK is a country where 
high quality and homogenous universal health care is provided to its residents free of charge 
irrespective of socioeconomic and other statuses. This made our cohort a true 
representative of the general population avoiding bias due to skewed demographics. Certain 
factors that are known to affect pregnancy outcome, such as ethnicity, parity, maternal age 
and BMI, socio economic deprivation, smoking status and pre-pregnancy insulin-dependent 
diabetes mellitus, have been adjusted for in our analysis. We have made an effort to look 
for lesser researched possible associations such as miscarriage and neonatal/perinatal 
death. Despite these strengths, our study is not without limitations. The data for potential 
confounding factors (existing prognostic factors) was limited to that which is routinely 
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collected in our electronic maternity record as this was a retrospective study. Similarly, the 
outcomes are limited to those routinely recorded and thus it was not possible to look at 
different thresholds that might confer a more severe outcome e.g. birth weight <5th or 3rd 
customised centile or severe pre-eclampsia. However, as our study was designed to 
investigate the independent prognostic ability of first trimester factors with adverse 
outcome it can be argued that when a factor is prognostic this relationship will be stronger 
for higher thresholds for the same outcome. Although the databases used were not 
designed for this particular study they are populated by qualified health professionals and 
data was obtained from multiple sources to allow cross-referencing and checking of 
outcomes. The biochemistry data is part of the National Screening Programme and thus 
subject to the relevant quality assurance (UK National external quality assurance scheme 
(UKNEQAS), Edinburgh Royal Infirmary, UK and Downs syndrome screening quality 
assurance and support service (DQASS), University of Plymouth UK). Our sample was 
determined by the number of patients available with an electronic record and outcome data 
and thus not determined by a sample size calculation. Most confidence intervals were quite 
narrow, but we recognise that non-significant findings do not necessarily mean that no 
prognostic association exists, and may simply reflect a low power to detect genuine 
associations. Nevertheless, many confidence intervals were relatively narrow and the 
prognostic associations identified were often strongly significant 26. 
The clinical utilisation of CRL as an individual prognostic factor (i.e. outside of a model using 
it as a continuous factor) is less clear as standard care in the UK is for a single first trimester 
ultrasound to incorporate dating (using CRL) and NT for aneuploidy risk. Previous studies 
have assessed the prognostic value of difference in expected to observed CRL based on the 
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last menstrual period10, observed versus expected change in CRL in the first trimester27 and 
CRL as a continuous factor in multivariable analysis28. The use of CRL to date a pregnancy 
assumes that there is no growth variation within the first trimester nor association with 
factors such as fetal sex, maternal age or ethnicity29. A study from the Netherlands 
demonstrated that CRL in the first trimester was associated with an increased risk of 
adverse birth outcomes and postnatal growth acceleration28. As standard care in the UK is 
only to offer one first trimester ultrasound, thus it is not possible to assess CRL change and 
the use of the CRL to date the pregnancy does not allow the assessment of observed to 
expected CRL. We thus wished to assess whether CRL, measured between the 11+2-14+1 
week window, assessed as a continuous variable had a relationship with adverse pregnancy 
outcome i.e. in particular assessing extremes of the continuum.  
 
Interpretation 
The aim was to provide more evidence toward establishing if the prognostic factors of 
interest can be used to further inform the management of potential adverse outcomes, for 
example by increased surveillance for pregnant women at greater risk. The results showed 
evidence of associations between the potential prognostic factors and several outcomes, 
and the associations remained largely the same when the factors were considered in 
combination. Future work is now important to establish whether the findings from all 
prognostic factor studies are consistent by synthesising the evidence. 
The evidence from this study supports the need for women with pregnancies with a low 
PAPP-A  and increased NT being under Consultant led care and the recommendation within 
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the RCOG guidelines7 for increased surveillance for SGA in pregnancies with a low PAPP-A 
and supports this being extended to pregnancies in the first trimester with an increased NT. 
At present until a model is developed that can incorporate these factors as continuous 
variables it would be appropriate to use accepted thresholds of <5th centile for PAPP-A and 
>99th centile for NT. Due to the association with low PAPP-A and PTB and PE these 
pregnancies should be assessed comprehensively for other risk factors for PTB and 
consideration given to the commencement of aspirin prior to 16 weeks. Independent 
prognostic factors have a broad array of potential uses in both clinical practice and health 
research12. For instance, they help to define disease at diagnosis; they may be modifiable in 
order for interventions to improve outcomes; they aid the design and analysis of trials; they 
are confounders to consider in observational studies and unbalanced trials; and they are the 
building blocks of prognostic models 12. Prognostic factor research is therefore important to 
discover and evaluate such factors. 
We emphasise that our multivariable models were fitted to examine if there is evidence of 
an independent association between the potential prognostic factors of interest and the 
maternal and fetal outcomes after adjustment for known prognostic factors. Our objective 
was to assess the prognostic factors themselves and not on an overall prognostic model for 
individual risk prediction. This is especially important since there was no external data to 
validate such a model 13. Future work could use new datasets to develop individual risk 
prediction models in order to tailor treatment choices to the individual and to look at 
different thresholds for the outcomes e.g. severe PET. Such models should build on the 
findings of this study, in terms of the prognostic factors that were identified as important. 
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Conclusion 
When three first trimester potential prognostic factors are considered in combination there 
remains strong evidence of associations between: a) PAPP-A, NT, CRL and SGA, b) PAPP-A 
only with PTB, c) PAPP-A and CRL for PE, d) NT and miscarriage. Further work is required to 
assess the predictive ability of these factors in prediction models for adverse pregnancy 
outcome. 
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Table 1: Mother and fetus demographics and clinical features at the test. 
 Summary (N=12,592) 
Mother’s age (years) 30.6 (5.6) 
Gestational age at test (days) 88.2 (4.3) 
Parity (number) 1 [0,1] 
BMI 25.1 [22.4, 28.8] 
Deprivation score*, n (%) 
≤8.49 455 (3.6) 
8.5 – 13.79 846 (6.7) 
13.8 – 21.35 2629 (20.9) 
21.36 – 34.17 2992 (23.8) 
≥34.18 5495 (43.6) 
Missing 175 (1.4) 
Ethnicity, n (%) 
African-Caribbean 944 (7.5) 
South-Asian 2502 (19.9) 
Oriental 358 (2.8) 
Other mixed 898 (7.1) 
White 7879 (62.6) 
Not stated 11 (0.1) 
Assisted conception, n (%) 250 (2.0) 
Smoking status, n (%) 
Smoker 1569 (12.4) 
Non-smoker 10611 (84.3) 
Stopped during 
pregnancy 
412 (3.3) 
Pre-pregnancy insulin-dependent  
Diabetes mellitus, n (%) 
36 (0.3) 
Gender of baby, n (%) 
Male 6118 (48.6) 
Female 6435 (51.1) 
Missing 39 (0.3) 
Mean (standard deviation) or median [interquartile range] for continuous variables and n (%) for 
categorical variables; * Deprivation score calculated using the National Perinatal Epidemiology Unit 
Index of Multiple Deprivation (NPEU IMD) calculator. BMI: body mass index 
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Table 2: Number of events for each outcome in singleton pregnancies (N=12,592) and unadjusted 
association with PAPP-A, nuchal translucency and crown rump length and each outcome 
(univariable logistic regression). 
Outcome 
Number of 
events (%) 
PAPP-A (U/L) 
Nuchal 
translucency (mm) 
Crown rump 
length (mm) 
Odds ratio (95% CI), p-
value 
Odds ratio (95% 
CI), p-value 
Odds ratio (95% 
CI), p-value 
SGA (<10th 
customised 
centile) 
1824 (14.5) 
0.87 (0.85 to 0.90), 
<0.0001 
0.81 (0.72 to 0.91), 
<0.0001 
0.99 (0.99 to 
1.00), 0.065 
Pre-term birth 
(<37 weeks) 
852 (6.77) 
0.93 (0.90 to 0.97), 
<0.0001 
1.15 (1.00 to 1.32), 
0.053 
1.00 (0.99 to 1.01), 
0.730 
Pre-eclampsia 352 (2.80) 
0.92 (0.86 to 0.97), 
0.004 
0.90 (0.70 to 1.14), 
0.378 
1.01 (1.00 to 
1.02), 0.123 
Miscarriage 
(death prior to 
birth <24 weeks 
gestation) 
73 (0.58) 
0.97 (0.86 to 1.09), 
0.598 
1.94 (1.54 to 2.45), 
<0.0001 
1.02 (0.99 to 
1.05), 0.147 
Stillbirth (death 
prior to birth 
>24 weeks 
gestation) 
37 (0.29) 
0.81 (0.66 to 1.00), 
0.052 
0.77 (0.35 to 1.68), 
0.503 
0.97 (0.93 to 
1.01), 0.150 
Perinatal 
death* (Death 
between 24 
weeks gestation 
and 7 days after 
birth) 
73 (0.58) 
0.93 (0.82 to 1.05), 
0.245 
0.70 (0.39 to 1.23), 
0.213 
0.98 (0.95 to 
1.01), 0.160 
Neonatal death$ 
(Death between 
birth and 28 
days) 
38 (0.31) 
1.03 (0.89 to 1.20), 
0.686 
0.57 (0.25 to 1.29), 
0.176 
0.98 (0.95 to 1.02), 
0.432 
* Perinatal death includes stillbirths; $ neonatal death includes babies that die between birth and 7 
days after birth that are captured within the perinatal death category. SGA small for gestational age 
(birth weight<10th customised centile. Odds ratios indicate the effect of 1 –unit increase in the factor 
on the odds of the outcome.
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Table 3: Adjusted odds ratio estimates for the association between each adverse outcome and 
PAPP-A, nuchal translucency and crown rump length. 
Outcome 
PAPP-A (U/L) OR (95% 
CI), p-value 
NT (mm) OR (95% CI), 
p-value 
CRL (mm) OR (95% 
CI), p-value 
SGA (<10th customised 
centile) 
0.88 (0.85 to 0.91), 
<0.0001 
0.79 (0.70 to 0.89), 
<0.0001 
0.99 (0.99 to 1.00), 
0.057 
Preterm birth (<37 weeks) 
0.92 (0.88 to 0.97), 
<0.0001 
1.09 (0.93 to 1.27), 
0.313 
1.00 (0.99 to 1.01), 
0.624 
Pre-eclampsia toxaemia 
0.91 (0.85 to 0.97), 
0.003 
0.87 (0.67 to 1.12), 
0.287 
1.01 (0.99 to 1.02), 
0.325 
Miscarriage (death <24 
weeks gestation) 
1.01 (0.84 to 1.21), 
0.929 
1.75 (1.12 to 2.72), 
0.013 
1.03 (0.99 to 1.07), 
0.129 
Stillbirth (death >24 weeks 
gestation) 
0.71 (0.52 to 0.98), 
0.038 
0.69 (0.25 to 1.93), 
0.485 
0.94 (0.89 to 0.99), 
0.027 
Perinatal death (death 
between 24 weeks 
gestation and 7 days after 
birth) 
0.88 (0.73 to 1.06), 
0.173 
0.89 (0.43 to 1.83), 
0.746 
0.97 (0.93 to 1.01), 
0.110 
Neonatal death (death 
between birth and 28 
days) 
1.04 (0.85 to 1.29), 
0.687 
1.07 (0.39 to 2.93), 
0.896 
1.00 (0.95 to 1.05), 
0.919 
OR odds ratio; CI confidence interval; NT nuchal translucency; CRL crown rump length; SGA small for 
gestational age; all odds ratio estimates for PAPP-A, NT and CRL from separate multivariable models, 
adjusted for maternal age, BMI, parity, ethnicity, deprivation score, smoking status, IVF, and 
gestational diabetes. 
 
